» Articles » PMID: 18204440

PDK1 Regulates Cancer Cell Motility by Antagonising Inhibition of ROCK1 by RhoE

Overview
Journal Nat Cell Biol
Specialty Cell Biology
Date 2008 Jan 22
PMID 18204440
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

In three-dimensional matrices cancer cells move with a rounded, amoeboid morphology that is controlled by ROCK-dependent contraction of acto-myosin. In this study, we show that PDK1 is required for phosphorylation of myosin light chain and cell motility, both on deformable gels and in vivo. Depletion of PDK1 alters the localization of ROCK1 and reduces its ability to drive cortical acto-myosin contraction. This form of ROCK1 regulation does not require PDK1 kinase activity, but instead involves direct binding of PDK1 to ROCK1 at the plasma membrane; PDK1 competes directly with RhoE for binding to ROCK1. In the absence of PDK1, negative regulation by RhoE predominates, causing reduced acto-myosin contractility and motility. This work uncovers a novel non-catalytic role for PDK1 in regulating cortical acto-myosin and cell motility.

Citing Articles

Studying luminal A and B subtypes of breast cancer under paracrine secretion of fibro-blasts.

Jalilzadeh N, Barzgar Barough N, Karami M, Baghbanzadeh A, Velaei K Bioimpacts. 2024; 14(3):27591.

PMID: 38938757 PMC: 11199934. DOI: 10.34172/bi.2023.27591.


Proteolysis-free amoeboid migration of melanoma cells through crowded environments via bleb-driven worrying.

Driscoll M, Welf E, Weems A, Sapoznik E, Zhou F, Murali V Dev Cell. 2024; 59(18):2414-2428.e8.

PMID: 38870943 PMC: 11421976. DOI: 10.1016/j.devcel.2024.05.024.


3-Phosphoinositide-Dependent Kinase 1 as a Therapeutic Target for Treating Diabetes.

Xiang X, Shuya P, Jiamin Z, Zihan Z, Xumei Y, Jingjin L Curr Diabetes Rev. 2024; 21(4):47-56.

PMID: 38468518 DOI: 10.2174/0115733998278669240226061329.


A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway.

Park J, Zhang H, Kwak H, Gadhe C, Kim Y, Kim H Front Pharmacol. 2023; 14:1275749.

PMID: 38035024 PMC: 10687218. DOI: 10.3389/fphar.2023.1275749.


The Role of Cyanidin-3--glucoside in Modulating Oxaliplatin Resistance by Reversing Mesenchymal Phenotype in Colorectal Cancer.

Kurter H, Basbinar Y, Ellidokuz H, Calibasi-Kocal G Nutrients. 2023; 15(22).

PMID: 38004099 PMC: 10674439. DOI: 10.3390/nu15224705.